Web Research
Web Research — Tenet Healthcare (THC)
The Bottom Line from the Web
The web tells a more conflicted story than Tenet's filings do alone. Two facts the financials don't show: a June 2025 short-seller report from Fuzzy Panda Research alleging ~$168M of excess Medicare outlier payments, with FOIA records hinting at unreleased SEC documents — and a wave of insider selling worth ~$26M+ in the eight months through March 2026, including the CEO's $15M open-market sale. Meanwhile sell-side targets are sliding fast: Wells Fargo cut its target from $265 to $213 on May 1, 2026, Guggenheim from $283 to $252, and Morgan Stanley from $260 to $254 — all in one day, after a Q1 2026 print where revenue ($5.37B) missed estimates and same-store sales went flat. Underneath that, the CommonSpirit/Conifer transaction is materially reshaping 2026 GAAP earnings with ~$1.65B of one-time termination revenue.
What Matters Most
1. Fuzzy Panda short report alleges Medicare outlier fraud — and the SEC may already be looking. On June 11, 2025, Fuzzy Panda Research published a report ("The 'Notorious' THC") alleging Tenet collected ~$168M in excess Medicare outlier payments after its 2006 five-year Corporate Integrity Agreement expired, and accusing the company of charging private-jet costs to government programs and using undocumented immigrant newborns to secure Medicaid reimbursement. Fuzzy Panda also disclosed FOIA correspondence indicating the SEC holds documents responsive to its request that it declined to release under FOIA Exemption 7(A) — typically applied to active enforcement matters. Estimated potential fines: $675M–$845M. Source: fuzzypandaresearch.com, Yahoo Finance.
2. Heavy insider selling, zero buying, in the eight months pre-Q1 2026. Eighteen insider sales / zero purchases in the trailing six months per Quiver Quant. CEO Saumya Sutaria sold 78,762 shares at a weighted-average $190.78 on Sept 10, 2025 ($15.0M). Director Tammy Romo sold 27,500 shares ($5.6M) Nov 2025. EVP/GC Tom Arnst sold 32,000 shares ($7.5M). Principal Accounting Officer R. Scott Ramsey sold 21,339 shares ($4.6M, including 8,017 at $232.70 on Mar 2, 2026 — within four weeks of the all-time high). Combined insider sales over the last three months: $10.94M. None of the Form 4s indicate a Rule 10b5-1 plan. Source: secform4.com, Stocktitan Form 4.
3. Sell-side cut targets sharply on May 1, 2026 — three banks in one day. Wells Fargo: target reduced from $265 to $213 (kept Overweight); Guggenheim: $283 to $252; Morgan Stanley: $260 to $254. The cuts followed a Q1 2026 revenue miss ($5.37B vs $5.39B consensus) and flat same-store sales. Stock fell 2.5% to ~$180.90 on May 1. Consensus PT remains $216.72 (26 analysts), but the trajectory has reversed from late-2025 highs near $283. Source: Daily Political, Ticker Report, Benzinga.
4. CommonSpirit/Conifer buyback adds ~$1.65B of 2026 revenue but distorts GAAP comparability. On Feb 2, 2026, Tenet completed a transaction with CommonSpirit Health to redeem CommonSpirit's 23.8% stake in Conifer Health Solutions, with payments of ~$1.9B from CommonSpirit to Tenet over three years and a ~$540M redemption from Conifer. 2026 will record ~$1.65B revenue from contract termination, ~$500M tax expense, and ~$150M tax payments. Q1 2026 alone booked $413M of that revenue plus a ~$40M favorable non-recurring adjustment. The 2026 EBITDA guide ($4.49–$4.79B) explicitly EXCLUDES the termination revenue from "net operating revenues." Source: SEC Exhibit 99.1, Stocktitan 8-K.
5. Hospital segment margins compressed in Q1 2026 even as the consolidated number flattered. Hospital Adjusted EBITDA fell to $678M from $707M YoY; segment margin 16.7% from 17.5%, attributed to unfavorable payer mix (lower exchange admissions) and the absence of prior-year Medicaid supplemental revenue benefits. Same-store sales flat vs +2.9% the prior-year quarter. The Q1 beat was ambulatory-driven (USPI EBITDA +6.1% to $484M) — the hospital story weakened. Source: Stocktitan 8-K, StockStory.
6. CEO compensation jumped 75% to $43.1M in 2025. Saum Sutaria's total compensation rose from $24.66M (2024) to $43.11M (2025): $1.5M salary, $9.0M annual incentive payout (200% of target), $31.7M stock awards, $0.93M other. The 2025 AIP funded at maximum after Tenet's TSR ranked highest in peer group over 1-, 3-, and 5-year periods ending Dec 31, 2025. Say-on-Pay received 93% approval at the 2025 annual meeting. ISS Governance QualityScore is 1 (best decile). Source: Discounting Cash Flows, Stocktitan DEF 14A.
7. Cigna–Abrazo network dispute over reimbursement rates surfaced Dec 2025. In late December 2025, Cigna patients faced potential loss of access to Tenet's Abrazo Health network in Phoenix as the parties clashed over reimbursement rates for hospital and provider services. Material because Abrazo is a meaningful portion of Arizona hospital revenue and out-of-network classifications can compress payer mix in subsequent quarters. Source: Yahoo/Simply Wall St.
8. $2.25B debt refinancing locked in cheaper paper through 2032/33. Nov 2025 — Tenet issued $1.5B of 5.500% senior secured first lien notes due 2032 and $750M of 6.000% senior notes due 2033 to refinance higher-coupon debt. End-Q1 2026 net debt/Adj EBITDA at 2.24x; total long-term debt $13.13B against $2.97B cash and full $1.9B revolver availability. Source: Investing.com.
9. One Big Beautiful Bill Act (OBBBA) flagged as a 2027+ headwind. The 10-Q explicitly calls out potential pressures from U.S. healthcare policy changes including OBBBA beginning in 2027. Combined with Goldman Sachs' December 2024 downgrade citing "increasing concerns about policy risks," this is a recurring overhang the filings barely quantify. Source: Stocktitan 10-Q.
10. Capital return: 7.6% net shareholder yield, no dividend, share count down 7.9% LTM. Trefis classified THC as a "Capital Compounder": 7.9% reduction in shares outstanding over the trailing twelve months, 7.08% buyback yield. 2025 buybacks: 8.8M shares for $1.4B. Q1 2026: 1.35M shares for $318M; $1.17B authorization remaining. Source: Trefis, Stocktitan 10-Q.
Web-discovered Headline Metrics
Consensus PT (USD, 26 analysts)
Q1 CY2026 Adj EPS (USD, 15.7% beat)
Q1 CY2026 Revenue (USD B, miss)
Q1 Adj EBITDA Margin (%)
Buyback Yield (%)
CEO 2025 Total Comp (USD M)
Recent News Timeline
What the Specialists Asked
Insider Spotlight
Saumya Sutaria, M.D. — Chairman & CEO. Joined Tenet Jan 2019 as COO; CEO Sep 2021; Chairman Aug 2023. Pre-Tenet: 18 years at McKinsey & Company in healthcare and PE practices. UC San Diego M.D. with UCSF post-grad training. 2025 total comp $43.1M (vs $24.7M in 2024 / $18.5M in 2023). Beneficial ownership: 592,073 shares post Feb 2026 RSU vesting. Sold $15M (78,762 shares) on Sept 10, 2025 with no 10b5-1 plan disclosed.
Sun Park — EVP & CFO. 2025 total comp $7.37M ($700K salary, $2M bonus, $2.7M stock, $1.75M incentive). Held 31,629 shares post Feb 2026 RSU vesting. CFO sales appear to be tax-withholding events around RSU vests, not open-market sales — distinguishing his profile from peers.
Tom Arnst — EVP, Chief Admin Officer & GC. 2025 total comp $10.05M (notably $4M bonus). Sold a combined 32,000 shares for $7.5M in early March 2026 at $234–$239, near the year's highs.
Lone Pine Capital, Wellington, and Eminence Capital are the high-conviction Q4 2025 bulls. Lone Pine added 1.79M shares ($355M) — its first material stake. Wellington added 1.04M shares (+1,114%). Eminence took a new $225M position. Counter-positioned: Citadel cut 1.02M shares (-96.7%) and UBS AM cut 693K (-75.8%).
Industry Context
Hospital sector — for-profit operator dynamics. HCA Healthcare beat profit and revenue but kept its annual forecast unchanged, sending shares down nearly 5% — signaling that even sector leaders are facing reset expectations. The whole for-profit hospital cohort is contending with: (1) lower exchange enrollment after ARPA subsidy expiration, (2) Medicaid supplemental payment normalization, and (3) a continued shift from inpatient to outpatient settings.
OBBBA (One Big Beautiful Bill Act) is the policy tail risk. Tenet's own 10-Q calls out the OBBBA as a 2027+ pressure factor on Medicare and Medicaid economics. Goldman Sachs cited "increasing concerns about policy risks" in its Dec 2024 downgrade — those concerns have not gone away.
Outpatient migration is the structural tailwind. Tenet's 559 ASCs put it ahead of HCA on outpatient mix; the Q1 2026 USPI segment EBITDA growth of +6.1% on 10.6% revenue growth shows where the operating leverage actually lives in the business. Ambulatory acquisitions in 2025: 27 ASCs + 1 surgical hospital. Industry consolidation continues to favor scale players.
Data points in this report are drawn from Brave Search results, SEC filings, and full-text page reads collected on 2026-05-04. All figures in USD. Insider dollar values are rounded; full Form 4 details are linked above.